Tipranavir
- Generic Name
- Tipranavir
- Brand Names
- Aptivus
- Drug Type
- Small Molecule
- Chemical Formula
- C31H33F3N2O5S
- CAS Number
- 174484-41-4
- Unique Ingredient Identifier
- ZZT404XD09
- Background
Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.
- Indication
For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
- Conditions
- First Posted Date
- 2003-03-21
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 328
- Registration Number
- NCT00056641
- Locations
- 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
🇩🇪Boehringer Ingelheim Investigational Site, Stuttgart, Germany
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
- Conditions
- Interventions
- First Posted Date
- 2003-02-10
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 630
- Registration Number
- NCT00054717
- Locations
- 🇺🇸
1182.12.9 Boehringer Ingelheim Investigational Site, Berkeley, California, United States
🇺🇸1182.12.7 Boehringer Ingelheim Investigational Site, Norwalk, Connecticut, United States
🇺🇸1182.12.1 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.